ISSN 0303-5212
 
2026, Vol: 51, Issue: 1
51 / 1Current Issue Online FirstArchiveAims and ScopeAbstracting & IndexingMost Accessed ArticlesMost Downloaded ArticlesMost Cited Articles
Required files to be uploaded

Author_Certificate-old
Bank Reciept

Review Article 
RMJ. 2025; 50(3): 789-793


Assessing the schematic molecular insights to therapeutic potential of Brain-Derived Neurotrophic Factor in treating and managing glaucoma

Saeed Ahmad, Muhammad Usman Durrani, Abdul Munim, Muhammad Imran Ali, Asim Mehmood, Madeeha Minhas.


Abstract
Objective: To investigate the neuro-ophthalmic interface through Brain-Derived Neurotrophic Factor (BDNF) molecular activity and its therapeutic value in glaucoma treatment.
Methodology: The role of BDNF in neuroprotection for glaucoma was evaluated through studies published between 2010 and 2024, following the PRISMA 2020 methodology. The search included PubMed, Scopus, and other relevant databases using keywords related to glaucoma, BDNF, neuroprotection, and therapeutic interventions. A total of 45 studies were reviewed, and 10 studies met the criteria for further investigation. These studies focused on BDNF molecular pathways and their effect on retinal ganglion cell survival, along with corresponding BDNF-based clinical therapies. The evaluation of risk bias used the Cochrane Risk of Bias Tool and GRADE criteria to make assessments about evidence quality.
Results: We found that BDNF is a vital factor in sustaining retinal ganglion cells and regulating intraocular pressure, both of which are important for glaucoma pathology. Basic Fibroblast Growth Factor-based treatment methods showed promising results by protecting retinal ganglion cells from damage and improving cellular function in laboratory models. BDNF administration through advanced drug delivery techniques could help glaucoma patients maintain good vision while minimally advancing disease progression. Multiple therapeutic agents combined with BDNF produced beneficial effects that surpassed individual treatment results.
Conclusion: BDNF functions as a promising molecular target for glaucoma treatment, offering new opportunities to protect optic nerves together with disease modifications. Scientists should concentrate their research on developing ideal delivery systems and investigating the long-term effectiveness of BDNF-based treatments in clinical practice.

Key words: BDNF, neuroprotection, glaucoma, retinal ganglion cells, molecular therapy, neurotrophic factors, intraocular pressure.


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Saeed Ahmad
Articles by Muhammad Usman Durrani
Articles by Abdul Munim
Articles by Muhammad Imran Ali
Articles by Asim Mehmood
Articles by Madeeha Minhas
on Google
on Google Scholar

How to Cite this Article
Pubmed Style

Ahmad S, Durrani MU, Munim A, Ali MI, Mehmood A, Minhas M. Assessing the schematic molecular insights to therapeutic potential of Brain-Derived Neurotrophic Factor in treating and managing glaucoma. RMJ. 2025; 50(3): 789-793.

Web Style

Ahmad S, Durrani MU, Munim A, Ali MI, Mehmood A, Minhas M. Assessing the schematic molecular insights to therapeutic potential of Brain-Derived Neurotrophic Factor in treating and managing glaucoma. https://www.rmj.org.pk/?mno=248867 [Access: October 30, 2025].

AMA (American Medical Association) Style

Ahmad S, Durrani MU, Munim A, Ali MI, Mehmood A, Minhas M. Assessing the schematic molecular insights to therapeutic potential of Brain-Derived Neurotrophic Factor in treating and managing glaucoma. RMJ. 2025; 50(3): 789-793.


Vancouver/ICMJE Style

Ahmad S, Durrani MU, Munim A, Ali MI, Mehmood A, Minhas M. Assessing the schematic molecular insights to therapeutic potential of Brain-Derived Neurotrophic Factor in treating and managing glaucoma. RMJ. (2025), [cited October 30, 2025]; 50(3): 789-793.


Harvard Style

Ahmad, S., Durrani, . M. U., Munim, . A., Ali, . M. I., Mehmood, . A. & Minhas, . M. (2025) Assessing the schematic molecular insights to therapeutic potential of Brain-Derived Neurotrophic Factor in treating and managing glaucoma. RMJ, 50 (3), 789-793.


Turabian Style

Ahmad, Saeed, Muhammad Usman Durrani, Abdul Munim, Muhammad Imran Ali, Asim Mehmood, and Madeeha Minhas. 2025. Assessing the schematic molecular insights to therapeutic potential of Brain-Derived Neurotrophic Factor in treating and managing glaucoma. Rawal Medical Journal, 50 (3), 789-793.


Chicago Style

Ahmad, Saeed, Muhammad Usman Durrani, Abdul Munim, Muhammad Imran Ali, Asim Mehmood, and Madeeha Minhas. "Assessing the schematic molecular insights to therapeutic potential of Brain-Derived Neurotrophic Factor in treating and managing glaucoma." Rawal Medical Journal 50 (2025), 789-793.


MLA (The Modern Language Association) Style

Ahmad, Saeed, Muhammad Usman Durrani, Abdul Munim, Muhammad Imran Ali, Asim Mehmood, and Madeeha Minhas. "Assessing the schematic molecular insights to therapeutic potential of Brain-Derived Neurotrophic Factor in treating and managing glaucoma." Rawal Medical Journal 50.3 (2025), 789-793. Print.


APA (American Psychological Association) Style

Ahmad, S., Durrani, . M. U., Munim, . A., Ali, . M. I., Mehmood, . A. & Minhas, . M. (2025) Assessing the schematic molecular insights to therapeutic potential of Brain-Derived Neurotrophic Factor in treating and managing glaucoma. Rawal Medical Journal, 50 (3), 789-793.


Author LoginReviewer LoginEditorial PoliciesConflict of Interest PolicyPlagiarism PolicyAdvertising Policy

About Rawal Medical Journal

Publication, subscription and Editorial office PMA House G/220-B Liaquat Road, Rawalpindi. Phone: 051-555-9812, Fax: 051-553-7088 Email: drnkhokhar@ya ... Read more.



For best results, please use Internet Explorer or Google Chrome.

Contact Information